Parkinane LP

Trihexyphenidyl

Method of action: Anticholinergic, Antiparkinsonian, M-Holinoblocking

Treatment option: Parkinson Disease, Muscle Cramp, Parkinsonism, Excessive Salivation

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Parkinane LP

Quick Facts

Property	Description
Active Ingredient	Trihexyphenidyl Hydrochloride (Benzhexol)
Form	Extended-Release Capsule (Libération Prolongée)
Pharmacological Class	Anticholinergic Agent / Antimuscarinic Agent
Common Use	Symptomatic treatment for stiffness and tremor in Parkinsonism
Origin	Synthetic small molecule

What Type of Medicine is Parkinane LP?

Parkinane LP is a prescription-only pharmaceutical preparation identified by its active ingredient, Trihexyphenidyl Hydrochloride. It is chemically categorized as a potent Anticholinergic Agent, which is a specialized class of Antimuscarinic Agents used to manage certain involuntary movement symptoms. This compound is a synthetic small molecule that functions as a centrally-acting Antiparkinson Agent, primarily used to provide symptomatic treatment by helping to balance chemical messengers in the central nervous system. This approach is clinically recognized for its effectiveness in managing the motor complications associated with Parkinsonism.

The identity of this medication derives from the action of Trihexyphenidyl as an antagonist that dampens overactive nerve signals. It achieves this by performing a Central Cholinergic Receptor Blockade, acting against the neurotransmitter Acetylcholine.

Understanding the LP Formulation: Extended-Release Capsule

Parkinane LP is classified as a single-ingredient, Extended-Release Capsule whose specialized formulation is denoted by the LP (for Libération Prolongée, or Prolonged Release). This medication is specifically designed as a single-ingredient product for oral administration. The physical form as an Extended-Release Capsule is a distinguishing feature, differentiating it from immediate-release oral tablet or elixir forms of the same active compound.

This particular design utilizes pharmaceutical excipients to carefully control the dissolution and release of the medication over an extended period. The purpose of this prolonged release mechanism is to maintain steadier, more consistent therapeutic levels of the drug in the body, which can contribute to more continuous and reliable management of symptoms.

Regulatory References

published by the NIH

What side effects are possible with Parkinane LP?

Possible Side Effects and Safety Information

Trihexyphenidyl Hydrochloride (Parkinane LP) is an anticholinergic agent, and its safety profile is defined by effects related to the blockade of the cholinergic system, as documented in regulatory labeling. Adverse reactions are formally classified by frequency and by System-Organ Class (SOC).

Common reactions, frequently observed, include dryness of the mouth, blurred vision, dizziness, nervousness, and mild nausea. These anticholinergic effects are often more pronounced at the start of treatment but may diminish as therapy continues.

System-Organ Classifications and Serious Reactions

The most affected systems include the Nervous System (e.g., confusion, agitation), Eye Disorders (e.g., mydriasis, increased intraocular pressure), and Gastrointestinal Disorders (e.g., constipation, urinary retention).

Serious adverse reactions officially documented in labeling include the potential for acute angle-closure glaucoma, severe psychotic states (such as delirium or hallucinations), paralytic ileus, and the risk of fatal heat stroke/hyperthermia due to reduced sweating (anhidrosis).

Population-Specific Safety and Constraints

The regulatory safety profile includes specific considerations for vulnerable populations. Older adults (geriatric patients) are noted to be particularly susceptible to adverse effects, including confusion, cognitive impairment, and the precipitation of urinary retention.

Trihexyphenidyl is contraindicated in individuals with untreated narrow-angle glaucoma and a known hypersensitivity to the drug. Caution is required in patients with obstructive diseases of the genitourinary or gastrointestinal tracts. Additionally, the abrupt cessation of treatment should be avoided, as this may lead to a severe worsening of parkinsonian symptoms or the onset of Neuroleptic Malignant Syndrome (NMS).

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes overdose with Parkinane LP (Trihexyphenidyl) as presenting a severe anticholinergic intoxication syndrome. This requires immediate emergency medical attention due to the risk of life-threatening systemic outcomes.

Documented Overdose Manifestations

Domain	Official Regulatory Statements
Central Nervous System	Confusion, agitation, hallucinations, delirium, and severe drowsiness progressing to coma.
Peripheral Signs	Tachycardia (fast heart rate), hyperpyrexia (high fever), dilated pupils, flushing, dry skin, and urinary retention.

Required Emergency Actions

The most severe manifestations of overdose include circulatory failure, respiratory failure, and potential death. Untreated overdose is particularly dangerous for children.

Seek emergency medical attention immediately if an overdose is suspected. Contact emergency services if the individual is experiencing seizures, trouble breathing, or is unresponsive.

Management is symptomatic and supportive, focused on maintaining an adequate airway and correcting severe disturbances such as hypoxia and acidosis. The official label does not specify a distinct antidote, and the use of antiarrhythmic drugs for dysrhythmias is not recommended in this context.

Therapeutic Uses of Parkinane LP

What Parkinane LP Treats: Main Uses and Benefits

The primary therapeutic role of Parkinane LP (Trihexyphenidyl Extended-Release) is applied in situations involving certain distressing symptoms across relevant categories of movement disorders and their associated symptoms. The Extended-Release (LP) formulation is considered relevant for managing symptoms that interfere with daily comfort in contexts involving chronic motor fluctuations.

The medication is considered relevant for symptomatic management across various forms of Parkinsonism. It is commonly used to help with the symptoms of extrapyramidal disorders (EPS) that arise as a consequence of certain central nervous system medications, as well as for the manifestations of Parkinsonism, including its idiopathic, postencephalitic, and arteriosclerotic forms.

This medication is applied in clinical settings marked by the pronounced presence of motor symptoms like resting tremor, muscle stiffness or rigidity, and dystonia (painful, sustained muscle spasms). The medication may assist with easing the physical burden of these symptoms and supports the patient during difficult episodes. The core benefit contributes to easing the overall symptom load, which may assist with maintaining functional stability during symptomatic periods.

Quick Fact: Symptomatic Support
Symptoms Primarily Addressed	Resting tremor and muscle rigidity in Parkinsonism
Secondary Use	Managing drug-induced extrapyramidal symptoms
LP Formulation Role	Supports consistent, stable symptom management

Eligibility and Restrictions for Use

Who can and cannot use Parkinane LP? — Official Regulatory Information

This section outlines the populations for whom use of Parkinane LP (trihexyphenidyl hydrochloride) is contraindicated or requires specific caution, based on regulatory labeling.

Eligibility Classification	Population/Condition	Regulatory Status
Contraindicated	Known hypersensitivity to the drug or any component.	Prohibited
Contraindicated	Narrow-angle glaucoma.	Prohibited (Use may lead to blindness)
Caution / Close Observation Required	Geriatric patients (especially over 60).	Increased sensitivity; requires strict dosage regulation.
Caution / Close Observation Required	Obstructive diseases of the gastrointestinal or genitourinary tracts.	Risk of exacerbation due to parasympatholytic effects.
Caution / Close Observation Required	Elderly males with possible prostatic hypertrophy.	Risk of urinary retention due to parasympatholytic effects.
Close Observation Required	Patients with cardiac, liver, or kidney disorders, or with hypertension.	Not contraindicated, but mandates close monitoring.

Age-Related Eligibility: Safety and efficacy have not been established in the pediatric population. For geriatric patients, a lower starting dose is typically required due to increased sensitivity to anticholinergic effects.

Pregnancy and Lactation: Official eligibility status is not explicitly documented as contraindicated or allowed in the provided regulatory summaries, but use during pregnancy is advised only if clearly needed. The drug may suppress lactation and should be used with caution in nursing mothers.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official documentation establishes specific interaction constraints for co-administration with other medicines and substances. The primary interaction pattern is pharmacodynamic, resulting in the additive effects of the drug's anticholinergic properties.

Interaction Type	Interacting Substances and Constraints
Pharmacodynamic Interactions	The co-use of Parkinane LP with other atropine-like drugs or other parasympathetic inhibitors carries a documented risk of additive anticholinergic effects. This includes the potential for anhidrosis (impaired sweating) and hyperthermia (elevated body temperature).
Dose Adjustment Requirement	Concomitant use with Levodopa may reduce Levodopa's effectiveness by delaying its gastrointestinal absorption, necessitating a reduction in the usual dose of each medication. Co-administration with certain Tranquilizers also requires the adjustment of both drug dosages to manage effects.
Substance Interaction	The use of Alcohol may result in additive Central Nervous System (CNS) depressant effects, which increases the risk of drowsiness and dizziness. No known interactions are documented with food or non-alcoholic drinks.
Population-Specific Caution	The interaction risk leading to anhidrosis and hyperthermia is highlighted for the chronically ill, alcoholics, and those with CNS disease when co-administered with atropine-like drugs, especially in hot weather. Geriatric patients may exhibit increased sensitivity to the effects of this drug class.

Mechanism of Action

Central Acetylcholine Receptor Blockade

The mechanism of Parkinane LP begins with the active ingredient acting as a non-selective antagonist at Muscarinic Acetylcholine Receptors (mAChRs), especially in the striatum of the central nervous system. This Central Cholinergic Receptor Blockade suppresses the direct excitatory signaling mediated by Acetylcholine, which is the foundational step required to modulate the striatal neurochemical equilibrium.

Modulation of Striatal Neurotransmitter Ratios

The molecular blockade initiates a critical system-level cascade: modulation of striatal neurotransmitter ratios. By reducing the relative overactivity of the cholinergic system—which occurs due to dopamine deficiency—the drug modifies the resulting hyperactivity in the motor control system. This adjustment leads to the Modulation of Efferent Motor Signals, directly modulating the efferent signaling that governs muscle tone.

Sustained Receptor Occupancy (LP Mechanism)

The Extended-Release (LP) formulation is designed to provide continuous delivery of the active agent, ensuring a sustained duration of target occupancy at the central muscarinic receptors. This consistent engagement establishes a sustained alteration of the central physiological state by sustained stabilization of the modulated neurochemical ratio, reducing variability in the central modulation of motor signaling.

Dosage and Administration Information

How to Use Parkinane LP

Parkinane LP (Trihexyphenidyl Extended-Release) is administered as a capsule intended for oral ingestion. Its specific formulation as a prolonged-release product dictates a primary pattern of once daily use, which is designed to provide consistent drug delivery over an extended period. This contrasts with the immediate-release tablet form, which is typically taken in multiple divided doses throughout the day.

Administration and Dosage Protocol

The usage protocol follows a principle of individualized and gradual dose adjustment. Treatment for Parkinsonism usually initiates with a low dose of 1 mg daily. The dosage is subsequently increased in small increments, typically 2 mg, with a required interval of three to five days between adjustments until a suitable maintenance level is reached. The usual daily maintenance dosage often falls within the range of 6 to 10 mg. Higher total daily amounts, potentially up to 12 to 15 mg, may be required for certain forms of Parkinsonism, such as postencephalitic cases.

Key Procedural Instructions

Instruction	Detail
Form Integrity	The extended-release capsule must be swallowed whole and should not be crushed, chewed, or opened.
Meal Relationship	The medicine may be taken with or without food. Taking it before meals may help with dryness of the mouth, while taking it after meals is suggested if the medicine causes nausea or stomach upset.
Discontinuation	Abrupt withdrawal of treatment must be avoided, as a sudden cessation may lead to the acute return or exacerbation of symptoms.
Older Adults	For geriatric patients, treatment must begin at a low initial dosage and be titrated exceptionally gradually.

These official instructions define the required procedural steps for the correct use of this extended-release formulation.

Recent Clinical Evidence

Research evidence / Overview of studies for Parkinane LP

This overview describes the types of scientific research conducted on the active compound in Parkinane LP (Trihexyphenidyl) and outlines the research landscape and study findings, presented without clinical guidance or outcome guarantees.

Evidence for Use in Parkinsonism

Research was studied for use in conditions where Parkinsonism symptoms may vary in intensity or activity, including the idiopathic (unknown cause), postencephalitic, and arteriosclerotic forms of the disease. Study types available include older Randomized Controlled Trials (RCTs), as well as modern crossover studies that was evaluated in research exploring the compound alongside placebo or other treatments.

Research examined how the medicine was associated with changes in overall motor function, using tools like the Unified Parkinson’s Disease Rating Scale (UPDRS). Studies also specifically monitored outcomes related to specific motor features, such as tremor and rigidity. Findings describe patterns observed in the studies where measurements related to specific motor deficits were tracked. However, findings were mixed across studies, and some research described different patterns of change for rigidity compared to tremor. This evidence contributes to the broader evidence landscape.

Evidence for Drug-Induced Movement Symptoms (Extrapyramidal Symptoms)

The compound was evaluated in research exploring its use for outcomes describing episodic or acute changes often seen in drug-induced extrapyramidal symptoms (EPS). This research included both RCTs and systematic reviews that summarized controlled studies on addressing movement issues that can arise after starting certain other central nervous system medications. These studies monitored the change in various extrapyramidal movement disorders, including dystonia (sustained muscle spasms) and the parkinsonism symptoms that may be brought on by drug exposure.

Long-Term Evidence and Observation Periods

The research landscape includes studies that explore short-term symptom changes, but also includes summaries of long-term use. Follow-up durations were limited in many of the core clinical trials. However, the evidence base includes long-term summaries of clinical use that research describes in patient cohorts over periods extending up to five years.

What Remains Unclear in the Research Base

Despite the long history of the medicine's use, several research gaps and limitations exist. The core research was conducted during periods of increased symptom activity decades ago, and the evidence quality varies across studies. Comparative evidence is lacking for certain standard outcomes, and the findings were mixed regarding which motor symptoms may be influenced most. Crucially, the evidence largely describes the compound itself, and the comparative evidence is lacking for the specific extended-release (LP) capsule design against other treatments. Therefore, long-term effects are not fully established, and certainty remains low for many specific subgroup findings.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Parkinane LP (FAQ)

Q: Can I drink alcohol while I am on Parkinane LP?

Official product information indicates that the use of alcohol while taking this medication may result in additive Central Nervous System (CNS) depressant effects. This means that combining the medicine with alcohol may lead to an increased risk of side effects such as drowsiness and dizziness. Official sources note this potential interaction.

Q: How is the dose of Parkinane LP increased?

According to regulatory documents, treatment with Parkinane LP typically starts at a low initial dose and is increased gradually. The dosage is adjusted in small increments, following the specific titration schedule outlined in the product information. This gradual adjustment is intended to reach an appropriate maintenance dosage.

Q: What happens if I forget to take my dose of Parkinane LP?

If a dose is missed, official guidance describes that it may be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the information states that the missed dose should be skipped and the regular schedule continued. Regulatory information specifies that a double dose should not be taken to compensate for a missed dose.

Q: Is there a generic version of Parkinane LP available?

The active ingredient in Parkinane LP, Trihexyphenidyl Hydrochloride, is available in a generic formulation. This generic formulation is distinct from the specialized extended-release (LP) capsule design of Parkinane LP.

Q: What are the differences between the LP capsule and the immediate-release tablet form?

The primary difference lies in the release mechanism. The Extended-Release (LP) capsule is formulated for prolonged drug delivery, providing drug consistency over an extended duration. In contrast, official regulatory labeling describes the immediate-release tablet form as typically requiring multiple doses daily to achieve its effect.

How should Parkinane LP be stored and disposed of?

Official Storage and Disposal Instructions

Parkinane LP (Trihexyphenidyl Extended-Release) must be stored according to strict regulatory guidelines to maintain its stability.

Storage Requirement	Details
Temperature	Store at Controlled Room Temperature, 15 C to 30 C (59 F to 86 F). Do not freeze.
Protection	Keep in the original package to protect from moisture. The container must be tight and light-resistant.
Child Safety	The medicine must be kept out of the reach and sight of children.

For disposal, any unused or expired Parkinane LP must be discarded properly. Disposal should be carried out according to local regulations as defined by official competent organizations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

France

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z